Collectively, situating thyroid carcinoma-associated PSMB8 upregulation within this thymic proteasome context clarifies that PSMB8 marks an IFN-licensed antigen-processing program linked to T-cell surveillance, consistent with its favorable prognostic association observed in thyroid carcinoma (56), and aligns with broader data that immunoproteasome-high tumors often display inflamed microenvironments and improved outcomes under immunotherapy. This evidence concerns the gene IFNA1 and thyroid gland carcinoma.